Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C. Khullar V, et al. Among authors: cambronero j. Eur Urol. 2013 Feb;63(2):283-95. doi: 10.1016/j.eururo.2012.10.016. Epub 2012 Nov 6. Eur Urol. 2013. PMID: 23182126 Clinical Trial.
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE. Nitti VW, et al. Among authors: cambronero j. Int J Clin Pract. 2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194. Epub 2013 May 21. Int J Clin Pract. 2013. PMID: 23692526 Free PMC article.
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stölzel M, Herholdt C, MacDiarmid S; BESIDE study investigators. Drake MJ, et al. Among authors: cambronero j. Eur Urol. 2016 Jul;70(1):136-145. doi: 10.1016/j.eururo.2016.02.030. Epub 2016 Mar 8. Eur Urol. 2016. PMID: 26965560 Free article. Clinical Trial.
The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.
Batista JE, Kölbl H, Herschorn S, Rechberger T, Cambronero J, Halaska M, Coppell A, Kaper M, Huang M, Siddiqui E; BEYOND study group. Batista JE, et al. Among authors: cambronero j. Ther Adv Urol. 2015 Aug;7(4):167-79. doi: 10.1177/1756287215589250. Ther Adv Urol. 2015. PMID: 26445596 Free PMC article.
How should we address the diagnosis of overactive bladder in women?
Jiménez Cidre MA, López-Fando L, Esteban M, Franco A, Arlandis S, Castro D, Prieto L, Salinas J, Gutiérrez C, Gutiérrez Baños JL, Cambronero J; Grupo de investigación en Resultados de Salud en Urología Funcional y Urodinámica. Jiménez Cidre MA, et al. Among authors: cambronero j. Actas Urol Esp. 2016 Jan-Feb;40(1):29-36. doi: 10.1016/j.acuro.2015.08.007. Epub 2015 Oct 20. Actas Urol Esp. 2016. PMID: 26493277 English, Spanish.
[Severe infections of the soft tissues].
Cambronero JA, Yus S, Rogero S, López J, Jiménez M. Cambronero JA, et al. Enferm Infecc Microbiol Clin. 1989;7 Suppl 1:16-22. Enferm Infecc Microbiol Clin. 1989. PMID: 2490487 Review. Spanish. No abstract available.
53 results